

Calcium supplements for the prevention of osteoporosis in perimenopausal women

Submission date 15/01/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 07/03/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 08/03/2019	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Osteoporosis is a bone disease that occurs when the body loses too much bone, makes too little bone, or both. As a result, bones become weak and may break from a fall.

Frequently, calcium supplements are recommended for the prevention or the treatment of the osteoporosis.

The main objective of the present study is to confirm whether the treatment with the ossein-hydroxyapatite complex, a calcium supplement, is better tolerated than the treatment with calcium carbonate, another calcium supplement.

Who can participate?

Women in the perimenopausal period.

Perimenopause takes place over several years in advance of the menopause and can last for 4 to 8 years. Thus, women between 40 and 50 years that are in the perimenopausal period, according to their physicians, are included in the study.

Women with normal bone density or slightly reduced (what is called osteopenia) are included in the study.

What does the study involve?

As the study compares two different calcium supplements, a group of participants is treated with 2 tablets every 12 hours of ossein-hydroxyapatite complex, a calcium supplement, and the other with 1 tablet every 12 hours of calcium carbonate, another calcium supplement. In all the patients the treatment is taken through the mouth. The treatment will last for three years.

What are the possible benefits and risks of participating?

Participants enrolled in this study are receiving a treatment that could help them to prevent osteoporosis.

The studied treatments are usually well tolerated. Nevertheless, some people could have constipation, mild nausea, diarrhoea, abdominal disturbances and, very rarely, itchy skin.

Where is the study run from?

The study has been developed in different health centers in an outpatient setting, previously specified, of several Spanish cities (A Coruña, Alicante, Badajoz, Barcelona, Bilbao, Santander, Castellón, Guadalajara, Las Palmas, León, Lugo, Madrid, Murcia Tarragona, Valencia, Zamora and Zaragoza).

When is the study starting and how long is it expected to run for?

The study begun in 2002 and patient inclusion finished in 2008.

Who is funding the study?

The study is funded by Pierre Fabre Ibérica S.A.

Who is the main contact?

José Manasanch
(jose.manasanch@pierre-fabre.com)

Contact information

Type(s)

Scientific

Contact name

Dr José Manasanch

ORCID ID

<https://orcid.org/0000-0003-3633-8778>

Contact details

Ramon Trias Fargas, 7-9

Barcelona

Spain

08005

Additional identifiers

Protocol serial number

PROP-02A

Study information

Scientific Title

Pharmacovigilance observational study of two calcium supplements in the prophylaxis of the osteoporosis in the perimenopause: a longitudinal study

Acronym

PROP

Study objectives

To confirm that ossein-hydroxyapatite complex shows a higher tolerability than calcium carbonate.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study did not require ethics approval at the time of initiation as in 2002, in Spain, ethics approval was not mandatory for observational studies related to pharmacovigilance using registered and marketed calcium supplements in an approved indication.

It was approved by the Spanish Medicines Agency, Ministry of Health on the 05/03/2002.

Study design

Observational, multicentre, prospective, open-label, comparative study with a follow-up of three years.

Primary study design

Observational

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Osteopenia

Interventions

Patients in the ossein-hydroxyapatite complex (OHC) arm took two tablets of OHC every 12 hours (830 mg OHC per tablet), by oral route, along three years.

Patients in the calcium carbonate (CC) group took one tablet every 12 hours (1,250 CC mg per tablet), by oral route, along three years.

As an observational study, carried out in the real-world practice, there were no randomisation.

Intervention Type

Supplement

Primary outcome(s)

Measured using patient interview at follow-up visits every 6 months for 3 years:

1. The number of patients with at least one adverse reaction
2. The severity of the adverse reaction.
3. The relationship of the adverse reaction with the study medication
4. The actions taken in response to the adverse reaction.
5. The outcome of the adverse reaction.
6. The duration of the adverse drug reaction

Key secondary outcome(s)

1. Bone mineral density was measured by DEXA every 18 months.
2. BMI (kg/m²) was measured every 18 months.

3. The waist hip ratio (%) was measured every 18 months.
4. Lipid metabolism was measured using laboratory analytical data yearly.
5. Bone fractures taking place during the study period were registered at each 6-month follow-up visit.
6. Climacteric (menopausal) symptom changes were measured using the GEM scale every 18 months.
7. Treatment compliance was assessed by means of patient interview at each follow-up (every 6 months).

Completion date

12/07/2011

Eligibility

Key inclusion criteria

1. Patients with an indication for the use of CC or OHC according to the investigator criteria.
2. Perimenopausal women between 40 and 50 years old.
3. Patients treated in an outpatient setting.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

1. Patients with severe osteopenia (diagnosed by DEXA, bone mineral density [BMD] ≤ -2 standard deviation [SD] T-score) or osteoporosis (BMD ≤ -2.5 SD T score)
2. Patients who were being treated with a drug that could have compromised bone metabolism such as: glucocorticoids, steroids, thyroid hormones, heparins (in long-term treatment), anticonvulsants, anovulatory drugs, hormone replacement therapy, lithium, chemotherapy, selective estrogen-receptor modulator (SERM), immunosuppressive therapy, and bisphosphonates. A minimal washout period of 6 months was established for any of the previous treatments prior to including the patient in the study.
3. Patients with severe hypercalcaemia or hypercalciuria.
4. Pregnant patients.
5. Concomitant diseases that could have affected bone metabolism: acromegaly, hyperthyroidism, primary hyperparathyroidism, anorexia nervosa, Cushing's syndrome, rheumatoid arthritis, renal diseases, renal lithiasis, diabetes mellitus, and chronic liver disease.
6. Concomitant metabolic bone disease: osteomalacia, Paget's disease.
7. Neoplastic disease developed in the last 5 years, with the exception of skin neoplasias treated with a radical treatment.
8. Known allergy to any compound of the study drugs.
9. Gastrointestinal disorders that could interfere with drug absorption.
10. Women with an expected difficult follow-up due to psychological, cognitive or social

circumstances.

11. Patients with foreseen low compliance, difficult follow-up and/or poor collaboration, or with foreseen risk of withdrawal over a minimum period of 3 months due to dementia, alcoholism, terminal illness, etc.

Date of first enrolment

25/07/2002

Date of final enrolment

02/06/2011

Locations

Countries of recruitment

Spain

Study participating centre

Centro Ntra Sra Belén

Teniente Coronel Teijeiro, 3

A Coruña

Spain

15011

Study participating centre

H G U Alicante

Pintor Baeza, 11

Alicante

Spain

03010

Study participating centre

H Alcoy

Caramanxel, s/n

Alcoy

Spain

03804

Study participating centre

Clinica ginecológica

Padre Manjon, 15

Alicante

Spain

03600

Study participating centre

Clínica ginecológica

Rbla Mendez Nuñez, 43

Alicante

Spain

03002

Study participating centre

H Don Benito

Ctra. Don Benito-Villanueva, Km 3

Don Benito

Spain

06400

Study participating centre

Clínica ginecológica

Rosselló, 161

Barcelona

Spain

08036

Study participating centre

H Mar

P Marítim Barceloneta, 25

Barcelona

Spain

08003

Study participating centre

Marti-Julia

Av Baix Llobregat, 17

Barcelona

Spain

08940

Study participating centre

Centro Casagemas

Riera de Matamoros, s/n

Barcelona
Spain
08911

Study participating centre
Clínica ginecológica
Av. Constitució, 177
Castelldefels
Spain
08860

Study participating centre
Doctor Barraquer
Dr. Trueta, s/n
Barcelona
Spain
08930

Study participating centre
Clin Quiron Barcelona
Alfonso Comín, 5
Barcelona
Spain
08023

Study participating centre
Clínica ginecológica
Gordóniz Kalea, 6
Bilbao
Spain
48010

Study participating centre
H U Marqués Valdecilla
Valdecilla, 25
Santander
Spain
39008

Study participating centre

C E Jaime I

Trullols, 3

Castellón

Spain

12001

Study participating centre

H G Castellon

Av Benicàssim, s/n

Castellón

Spain

12004

Study participating centre

H U Guadalajara

Donante de Sangre, s/n

Guadalajara

Spain

19002

Study participating centre

H U Materno-Infantil

Av Marítima del Sur, s/n

Las Palmas G. Canaria

Spain

35016

Study participating centre

Clin N S Perpetuo Socorro

Leon y Castillo, 407

Las Palmas G. Canaria

Spain

35007

Study participating centre

H León

Altos de Navas, s/n

León

Spain

24008

Study participating centre

H Materno-Infantil

Dr Severo Ochoa, s/n

Lugo

Spain

27004

Study participating centre

H Sta. Cristina

Amadeo Vives, 2

Madrid

Spain

28009

Study participating centre

H La Paz

P Castellana, 261

Madrid

Spain

28046

Study participating centre

CMS Tetuán

Aguileñas, 1

Madrid

Spain

28029

Study participating centre

H U Mostoles

Río Júcar, s/n

Móstoles

Spain

28934

Study participating centre

H M Central de la Defensa

Glor Ejército, 1

Madrid
Spain
28047

Study participating centre

Clínica ginecológica

Angeles, 16
Torrelodones
Spain
28250

Study participating centre

H U Getafe

Ctra Madrid - Toledo, Km 12.500
Madrid
Spain
28905

Study participating centre

Inst Palacios

Antonio Acuña, 9
Madrid
Spain
28009

Study participating centre

H Ramón y Cajal

Ctra Colmenar Viejo, Km 9,1
Madrid
Spain
28034

Study participating centre

Clínica ginecológica

Jabonerías, 9
Murcia
Spain
30001

Study participating centre
Clínica Monegal
Av President Companys, 12
Tarragona
Spain
43005

Study participating centre
Clínica ginecológica
Av Blasco Ibáñez, 108
Valencia
Spain
46021

Study participating centre
C E Monteolivete
Escultor José Capuz, 13
Valencia
Spain
46006

Study participating centre
H Arnau Vilanova
Sant Clement, 12
Valencia
Spain
46015

Study participating centre
Clínica ginecológica
Bèlgica, 1
Valencia
Spain
46021

Study participating centre
H U La Ribera
vCtra. Corbera, km 1
Alzira
Spain
46600

Study participating centre

Clínica ginecológica

Moralets, 21

Torrent

Spain

46900

Study participating centre

Clínica reumatológica

Dr Manuel Candela, 41

Valencia

Spain

46021

Study participating centre

C E Trinitat

La Flora, 7

Valencia

Spain

46010

Study participating centre

Clínica ginecológica

Alfonso Peña, 7

Zamora

Spain

49010

Study participating centre

Pol Adeslas

Carmen, 22

Zaragoza

Spain

50005

Study participating centre

Centro Med Zaragoza

Gran Vía, 27

Zaragoza
Spain
50006

Study participating centre

Clinica Aisa
P San Lamberto, 10
Zaragoza
Spain
50004

Sponsor information

Organisation

Javier Haya Palazuelos

Funder(s)

Funder type

Industry

Funder Name

Pierre Fabre Ibérica, S.A.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from José Manasanch, jose.manasanch@pierre-fabre.com.

The data (raw data and statistical analysis) will become available as soon as the results will be published and could be requested for a minimum of three years after this date if needed for investigational purposes. A formal request will be necessary.

Patients meeting the selection criteria were included in the study after providing informed consent that remain in the investigator files. Any data from the patients was anonymized from inclusion in the study.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Abstract results	results presented at EMAS Congress :	01/05/2015		No	No
Basic results		22/01/2019		No	No